Encouraging Panelists’ Donations for Cancer Research, Matching Them $ for $

Miami, FL, June 8, 2018   Medimix International today announced that it has launched a campaign to support cancer research by proposing to the members of its global HCP community to match dollar for dollar the portion of their honoraria they would donate for research against cancer.  The first donations will go to the Cancer Research Institute, one of the highest ranked charities for cancer research.

How Close are We to a Cure?

It has been more than sixty years since the war on cancer was declared.  The National Cancer Institute and other institutions has spent billions of dollars on cancer research, and we now know better about the causes of cancer, how cancer cells grow and spread, and we continue to discover new ways to target and kill tumor cells.  

However, the statistics tell us that the battle has not yet been won. The International Agency for Research on Cancer reports that cancer is one of the leading causes of death worldwide, and the number of new cancer cases per year is expected to rise to 23.6 million by 2030.   In the USA in 2018 alone, 1,735,350 new cancer cases will be diagnosed, and 609,640 will die from their disease.

The Race for a Cure is a Marathon

In reality,  the “race for a cure” is a marathon that depends not only on the testing of drugs in development by international pharmaceutical companies but even more on the thousands of scientists around the globe conducting research at hospitals, universities, and other non-commercial institutions. 

 “Funding for this research remains lower than it was before the 2008 recession, and has remained flat over the last decade. We want to be part of the solution and help support these scientists who play such an important role,” commented Henry Gazay, Medimix CEO.

“We realize that cancer is a complicated target,” he added, “because each type of cancer varies from the others and all have different molecular signatures.  So there is no one silver bullet, and we all need to do what we can to help maintain the pace of scientific discovery.” 

There is Hope on the Horizon

Every day brings word of scientific advances in identifying genetic mutations that may indicate a predisposition to develop cancer. Knowing which mutations are responsible generates revolutionary breakthroughs that allow for the repair of damaged genes with oncogenes (e.g., HER2, RAS) or by employing tumor suppressor genes, such as BRCA1, BRCA2 and p53, or using other therapeutic agents such as PD-L1 to harness and enhance the innate powers of our own immune system.

Medimix International Wants to Make a Difference

Medimix has a long history of partnering with the pharma industry to understand treatment algorithms and standards of care. For more than 25 years, Medimix has been providing strategic information and insights to inform the industry and is currently studying how cancer patients are being identified, which biomarkers tested, which treatments are offered and their outcomes.

Over the years, Medimix has developed a trusted relationship with its global panel of HCPs, of which more than 20,000 specialize in oncology, and in the spirit of collaboration and partnership, has offered its support for its panelists by proposing to match dollar for dollar the portion of their honoraria they choose to donate for research against cancer. This year the donations will go to the Cancer Research Institute, one of the highest ranked charities for cancer research which supports 3,100 scientists globally, with 86% of the proceeds of donations going directly to researchers.

As Medimix CEO, Henry Gazay remarked, Medimix wants to share the message that if all of us give a little bit to fund breakthrough cancer research, together we can make a big difference.  In 2018, Medimix will pay millions of dollars in honoraria to HCPs who report Real World Evidence in our platform.  If they agree to donate on average only 5% of it to cancer research, and with Medimix matching $ for $, this is potentially hundreds of thousands of dollars that will go directly to cancer research. This is a powerful example of how each and everyone of us can help. We think we are on the right path.”  



Since 1989, Medimix International has served the Top 50 pharma companies and is a leading provider of  Real World Insights. Through the syndicated LiveTrackerTM series, a global panel of HCPs reports real time data across 40 countries on 22 oncology and hematology indications, which is analyzed and published monthly on a cloud-based platform. Information focuses on product usage and performance as well as the patient journey.

With International Headquarters in Miami, Medimix International’s multi-lingual, multi-cultural staff is located in 12 cities around the globe: United States – Boston, San Francisco, and NJ; EU – Paris, London, and Basel; LatAm – Montevideo, Uruguay and Sao Paulo, Brazil; Asia: Bacolod, Hong-Kong, Tokyo and Shanghai.